2024
Measurement invariance of the perceived stress scale across race, sex, and time, and differential impacts on cocaine use treatment outcomes
Schick M, Kiluk B, Nich C, LaPaglia D, Haeny A. Measurement invariance of the perceived stress scale across race, sex, and time, and differential impacts on cocaine use treatment outcomes. Journal Of Substance Use And Addiction Treatment 2024, 209493. PMID: 39151798, DOI: 10.1016/j.josat.2024.209493.Peer-Reviewed Original ResearchCocaine use disorderPerceived Stress ScaleTreatment retentionMeasurement invarianceTreatment outcomesSubstance use treatment outcomesStress ScalePredicting treatment retentionSelf-efficacyCoping self-efficacyTwo-factor modelInfluence treatment outcomeCocaine abuse/dependenceDSM-IVUse disorderCocaine useBetween-group differencesMetric invarianceScalar invarianceTwo-factorCocainePharmacological treatmentFactor analysisDifferential impactAbuse/dependence
2023
Percentage of negative urine drug screens as a clinically meaningful endpoint for RCTs evaluating treatment for cocaine use
Loya J, Babuscio T, Nich C, Alessi S, Rash C, Kiluk B. Percentage of negative urine drug screens as a clinically meaningful endpoint for RCTs evaluating treatment for cocaine use. Drug And Alcohol Dependence 2023, 248: 109947. PMID: 37276806, PMCID: PMC10498479, DOI: 10.1016/j.drugalcdep.2023.109947.Peer-Reviewed Original ResearchConceptsUrine drug screensClinical trialsMeaningful endpointsCocaine useLong-term clinical benefitBetter long-term outcomesDrug screensPsychosocial functioningNegative urine drug screensLong-term outcomesRandomized clinical trialsFuture clinical trialsBetter psychosocial functioningClinical benefitPharmacological treatmentContinuous abstinenceTreatment periodTreatment respondersSustained abstinenceSubstance useTrialsTreatmentMeaningful thresholdPooled datasetAbstinence